Emerging Companies

There are many reasons to be excited about financing early stage biotech companies. The BIO Investor Forum will assemble the most promising among promising discovery stage companies. 

In this global economy, nearly every competitor has access to big breakthroughs in technology and to the equipment and capital to produce standardized products, but those regions that possess the human capital, with its insights, competencies, and experience will have the competitive advantage.

Pete Pellerito discusses what is being done to provide the workforce for this broad and growing industry.

FasterCuresis a nonpartisan organization that works to improve the medical research system to speed up the time it takes to get important new medicines from discovery to patients.

Jack discusses her greatest accomplishments, advice for industry leaders, and the promise of biotech. Pulmatrix is a clinical trial stage biotech company based in Lexington, Mass.

The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.

On July 26, Agriculture Secretary Tom Vilsack announced four new project areas for the Biomass Crop Assistance Program.

With more than one-fifth of the world’s population, China is an important market for biotech products and is increasingly a key global player in biotech research, development and manufacturing.

What is your opinion of biotechnology companies – very favorable, somewhat favorable, somewhat unfavorable, or very unfavorable?

Ever wonder what it takes to host 20,000 one-on-one meetings at BIO International Convention?

BIOtechNOW’s Tracy Cooley talks to Dr. Schubert of the  Bioscience Association of West Virginia about biotech in West Virginia – major areas of growth, the outlook for growth of the industry within the states, and plans for the upcoming  BIO International Convention.

Biofuels Digest and BIO have launched the Summer 2011 Bioenergy Business Outlook Survey.

BIO and five member companies – Mendel Biotechnology, Arborgen, Abengoa Bioenergy, Novozymes and BP Biofuels – along with the Biomass Power Association held a briefing on Capitol Hill this week, outlining the importance of the USDA’s Biomass Crop Assistance Program (BCAP) and related programs. Regulatory rules for the BCAP, Biorefinery Assistance Program, and Rural Energy for America Program (REAP) were finalized by USDA only during the last quarter of 2010. But Congress is considering cutting the funds for these programs before they have a chance to show their effectiveness.

The Biotechnology Entrepreneurship Boot Camp at the 2011 BIO International Convention is an intensive three day course designed for entrepreneurial scientists.

November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.
March 16 2012
On behalf of BIO and its more than 1,100 members, Jim Greenwood submitted a letter to Senate Majority Leader Harry Reid and Minority Leader Mitch McConnell in strong support of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act.
March 6 2012
William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth across the country.
April 9 2014
The House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled “Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies.” Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.
April 7 2014
The EXPIRE Act would extend tax credits that expired at the end of 2013, including several of importance to the biotechnology industry.
February 12 2014
Bill would spur capital formation for small public companies
December 19 2013
More than 140 Companies Expected to Present Their Story to Top Public and Venture Capital Investors